Advertisement

Drug Safety

, Volume 42, Issue 1, pp 55–66 | Cite as

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case–Control Study

  • Noel Frey
  • Michael Bodmer
  • Andreas Bircher
  • Susan S. Jick
  • Christoph R. MeierEmail author
  • Julia Spoendlin
Original Research Article

Abstract

Introduction

Stevens–Johnson syndrome and toxic epidermal necrolysis have been associated with the use of various drugs, but evidence is scarce. We studied the association between new use of outpatient drugs other than anti-epileptic drugs and antibiotics and Stevens–Johnson syndrome and toxic epidermal necrolysis.

Methods

We conducted a matched (1:4) case–control analysis in 480 previously validated Stevens–Johnson syndrome/toxic epidermal necrolysis cases (1995–2013). We calculated odds ratios with 95% confidence intervals for Stevens–Johnson syndrome/toxic epidermal necrolysis in new users of drugs compared to non-users. For cases of Stevens–Johnson syndrome/toxic epidermal necrolysis diagnosed ≤ 84 days after the first use of a drug, we assessed causality between drug exposure and Stevens–Johnson syndrome/toxic epidermal necrolysis using ALDEN (algorithm of drug causality in epidermal necrolysis). We calculated absolute risks by dividing the number of Stevens–Johnson syndrome/toxic epidermal necrolysis cases ≤ 84 days after new drug exposure by the total number of new users of the drug.

Results

There was an association between Stevens–Johnson syndrome/toxic epidermal necrolysis and the use of allopurinol (odds ratio 24.51, 95% confidence interval 2.94–204.04) and cyclooxygenase-2 inhibitors (odds ratio 24.19, 95% confidence interval 2.91–200.92). Proton pump inhibitors, fluoxetine, mirtazapine, and 5-aminosalicylates (sulfasalazine, mesalamine) were also associated with an increased risk of Stevens–Johnson syndrome/toxic epidermal necrolysis, though with lower odds ratios. ALDEN score application suggests a likely causality for these associations. Absolute risks of Stevens–Johnson syndrome/toxic epidermal necrolysis were 6.0/100,000 new users for allopurinol, and 1.9–4.3/100,000 new users for cyclooxygenase-2 inhibitors and 5-aminosalicylates, and 0.2–1.6/100,000 new users for proton pump inhibitors, fluoxetine, and mirtazapine. We found no association between Stevens–Johnson syndrome/toxic epidermal necrolysis and oxicams, benzodiazepines, citalopram, sertraline, paroxetine, venlafaxine, and phosphodiesterase-5 inhibitors despite > 100,000 new users.

Conclusions

In this observational study, we observed likely causal associations between Stevens–Johnson syndrome/toxic epidermal necrolysis and use of allopurinol, cyclooxygenase-2 inhibitors, and 5-aminosalicylates, and potential associations for proton pump inhibitors, fluoxetine, and mirtazapine.

Notes

Acknowledgments

We thank Pascal Egger for programming and technical support.

Compliance with Ethical Standards

Funding

This study was supported by the University of Basel Science Foundation (Grant No. DMS2297).

Conflict of Interest

Noel Frey, Michael Bodmer, Andreas Bircher, Susan S. Jick, Christoph R. Meier, and Julia Spoendlin have no conflicts of interest that are directly relevant to the content of this study.

Supplementary material

40264_2018_711_MOESM1_ESM.pdf (244 kb)
Supplementary material 1 (PDF 243 kb)
40264_2018_711_MOESM2_ESM.pdf (289 kb)
Supplementary material 2 (PDF 289 kb)
40264_2018_711_MOESM3_ESM.pdf (282 kb)
Supplementary material 3 (PDF 282 kb)
40264_2018_711_MOESM4_ESM.pdf (325 kb)
Supplementary material 4 (PDF 324 kb)
40264_2018_711_MOESM5_ESM.pdf (206 kb)
Supplementary material 5 (PDF 206 kb)

References

  1. 1.
    Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015 Jul;13(7):625–45.Google Scholar
  2. 2.
    Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med. 2011;39(6):1521–32.CrossRefGoogle Scholar
  3. 3.
    Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy. 2012 Jan;97:149–66.CrossRefGoogle Scholar
  4. 4.
    Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008 Jan;128(1):35–44.CrossRefGoogle Scholar
  5. 5.
    Roujeau J, Kelly J, Naldi L, Rzany B, Stern R, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–7.CrossRefGoogle Scholar
  6. 6.
    Jonsson GW, Moosa MY, Jeenah FY. Toxic epidermal necrolysis and fluoxetine: a case report. J Clin Psychopharmacol. 2008;28(1):93–5.CrossRefGoogle Scholar
  7. 7.
    Wolkenstein P, Revuz J, Diehl J, Langeron O, Roupie E, Machet L. Toxic epidermal necrolysis after fluvoxamine. Lancet. 1993;342(8866):304–5.CrossRefGoogle Scholar
  8. 8.
    Tudela E, Villier C, Mallaret M. Toxic epidermal necrolysis associated with paroxetine. Gen Hosp Psychiatry. 2009 Jan;31(3):297–8.CrossRefGoogle Scholar
  9. 9.
    Belkahia A, Hillaire-Buys D, Dereure O, Guillot B, Raison-Peyron N. Stevens-Johnson syndrome due to mirtazapine: first case. Allergy. 2009 Oct;64(10):1554.CrossRefGoogle Scholar
  10. 10.
    Strawn J, Whitsel R, Nandagopal J, Delbello M. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine. J Child Adolesc Psychopharmacol. 2011;21(1):91–2.CrossRefGoogle Scholar
  11. 11.
    Weiss N, Jones L, Chamberlain J. A possible case of venlafaxine-induced Stevens-Johnson syndrome. J Clin Psychiatry. 2004;65(10):1431–3.CrossRefGoogle Scholar
  12. 12.
    Casacci M, Lebas D, Decamps F, Fourrier F, Delaporte E. Toxic epidermal necrolysis due to omeprazole. Eur J Dermatol. 2006;16(6):699–700.Google Scholar
  13. 13.
    Heaton N, Edmonds E, Francis N, Bunker C, Bowling J, Morar N. Fatal toxic epidermal necrolysis due to lansoprazole. Clin Exp Dermatol. 2004;29(6):612–3.CrossRefGoogle Scholar
  14. 14.
    Moubayed D, Gifuni A, Tourian L. Methotrimeprazine-associated Stevens-Johnson syndrome in 2 Ashkenazi Jewish patients. J Clin Psychopharmacol. 2017;37(1):112–3.CrossRefGoogle Scholar
  15. 15.
    Kumar P, Chauhan A, Haraniya R, Ghosh A, Tandon V. Metolazone associated Stevens Johnson syndrome-toxic epidermal necrolysis overlap. J Clin Diagn Res. 2016;10(3):01–2.Google Scholar
  16. 16.
    Jao T, Tsai T-H, Jeng J-S. Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome. Br J Clin Pharmacol. 2009 Feb;67(2):264–5.CrossRefGoogle Scholar
  17. 17.
    Struye A, Depuydt C, Abdel-Sater E, Dubois V. Toxic epidermal necrolysis related to paliperidone palmitate: first case report. J Clin Psychopharmacol. 2016;36(3):279–82.CrossRefGoogle Scholar
  18. 18.
    Yang C-Y, Chen C-H, Wang H-Y, Hsiao H-L, Hsiao Y-H, Chung W-H. Strontium ranelate related Stevens-Johnson syndrome: a case report. Osteoporos Int. 2014 Jun;25(6):1813–6.CrossRefGoogle Scholar
  19. 19.
    Surovik J, Riddel C, Chon S. A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation. J Drugs Dermatol. 2010;9(8):1010–2.Google Scholar
  20. 20.
    Pretel-Irazabal M, Marquez-Martin L, Aguado-Gil L, Idoate-Gastearena M. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47(3):e16.CrossRefGoogle Scholar
  21. 21.
    Fukunaga K, Ohda Y, Inoue T, Kono T, Miwa H, Matsumoto T. Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis. Inflamm Bowel Dis. 2007 Aug;13(8):1055–6.CrossRefGoogle Scholar
  22. 22.
    La Grenade L, Lee L, Weaver J, Bonnel R, Karowski C, Governale L, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917–24.CrossRefGoogle Scholar
  23. 23.
    Delesalle F, Carpentier O, Guatier S, Delaporte E. Toxic epidermal necrolysis caused by tetrazepam. Int J Dermatol. 2006;45(4):480.CrossRefGoogle Scholar
  24. 24.
    Haddad C, Sidoroff A, Kardaun SH, Mockenhaupt M, Creamer D, Dunant A, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk? Drug Saf. 2013;36(8):681–6.CrossRefGoogle Scholar
  25. 25.
    Frey N, Bodmer M, Bircher A, Rüegg S, Jick SS, Meier CR, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. Epilepsia. 2017;58(12):2178–85.CrossRefGoogle Scholar
  26. 26.
    Frey N, Bircher A, Bodmer M, Jick SS, Meier CR, Spoendlin J. Antibiotic drug use and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based case-control study. J Invest Dermatol. 2018;138(5):1207–9.CrossRefGoogle Scholar
  27. 27.
    Herrett E, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.CrossRefGoogle Scholar
  28. 28.
    Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010 Jan;69(1):4–14.CrossRefGoogle Scholar
  29. 29.
    Frey N, Bircher A, Bodmer M, Jick SS, Meier CR, Spoendlin J. Validation of Stevens-Johnson syndrome or toxic epidermal necrolysis diagnoses in the Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2017;26(4):429–36.CrossRefGoogle Scholar
  30. 30.
    Lambertini M, Del Mastro L, Gardin G, Levaggi A, Bighin C, Giraudi S, et al. Stevens-Johnson syndrome after treatment with bendamustine. Leuk Res. 2012;36(7):153–4.CrossRefGoogle Scholar
  31. 31.
    Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz ES, Ficker JH, et al. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer. 2016;95:35–8.CrossRefGoogle Scholar
  32. 32.
    Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91(4):482–3.CrossRefGoogle Scholar
  33. 33.
    Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther. 2010;88(1):60–8.CrossRefGoogle Scholar
  34. 34.
    Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005 Apr 12;64(7):1134–8.CrossRefGoogle Scholar
  35. 35.
    Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221–5.CrossRefGoogle Scholar
  36. 36.
    Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240–7.CrossRefGoogle Scholar
  37. 37.
    Burns RA, Topoz I, Reynolds SL. Tumor lysis syndrome: risk factors, diagnosis, and management. Pediatr Emerg Care. 2014;30(8):571–6.CrossRefGoogle Scholar
  38. 38.
    de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. J Am Med Dir Assoc. 2013;14(4):265–9.CrossRefGoogle Scholar
  39. 39.
    Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194–227.CrossRefGoogle Scholar
  40. 40.
    Dang CD, Beets-Shay L, Kahn EC. Toxic epidermal necrolysis triggered by clobazam: a case report in a 13-year-old girl. Pediatr Dermatol. 2015;32(3):e102–3.CrossRefGoogle Scholar
  41. 41.
    Sánchez I, García-Abujeta JL, Fernández L, Rodríguez F, Quiñones D, Duque S, et al. Stevens-Johnson syndrome from tetrazepam. Allergol Immunopathol (Madr). 1998;26(2):55–7.Google Scholar
  42. 42.
    Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136:1387–97.CrossRefGoogle Scholar
  43. 43.
    Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau J-C. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol. 2002;138(8):1019–24.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Noel Frey
    • 1
    • 2
  • Michael Bodmer
    • 3
  • Andreas Bircher
    • 4
  • Susan S. Jick
    • 5
    • 6
  • Christoph R. Meier
    • 1
    • 2
    • 5
    Email author
  • Julia Spoendlin
    • 1
    • 2
  1. 1.Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical SciencesUniversity of BaselBaselSwitzerland
  2. 2.Basel Pharmacoepidemiology Unit, Hospital PharmacyUniversity Hospital BaselBaselSwitzerland
  3. 3.Internal MedicineCantonal HospitalZugSwitzerland
  4. 4.AllergologyUniversity Hospital BaselBaselSwitzerland
  5. 5.Boston Collaborative Drug Surveillance ProgramLexingtonUSA
  6. 6.Boston University School of Public HealthBostonUSA

Personalised recommendations